Pular para o conteúdo
Câncer de ovário raro
ORPHA:213500CID-10 · C56CID-11 · 2C73OMIM 167000DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
Audição

É um câncer que afeta o ovário, podendo ter começado nele (primário) ou se espalhado de outro lugar (metastático). A maioria dos cânceres primários de ovário são carcinomas (tipos comuns incluem o seroso, mucinoso ou endometrióide) ou tumores malignos de células germinativas (que se originam das células que formam os óvulos). Já os cânceres que se espalham para o ovário (metastáticos) podem ser carcinomas, linfomas (câncer do sistema linfático) e melanomas (um tipo de câncer de pele).

Em construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

O câncer de ovário raro reúne tipos incomuns de tumores malignos que atingem os ovários, podendo começar no próprio órgão ou vir de outras partes do corpo. Os sinais mais perceptíveis incluem dores abdominais constantes, aumento ou inchaço do abdômen e alterações hormonais como o excesso de pelos decorrente de níveis aumentados de testosterona. No Brasil, medicamentos oncológicos como paclitaxel contam com registro formal na ANVISA. O atendimento pelo SUS é conduzido segundo a autonomia do serviço médico local, de acordo com o protocolo oficial de neoplasia maligna epitelial de ovário.

📋
Informacoes curadas por IA — podem conter imprecisoes

É um câncer que afeta o ovário, podendo ter começado nele (primário) ou se espalhado de outro lugar (metastático). A maioria dos cânceres primários de ovário são carcinomas (tipos comuns incluem o seroso, mucinoso ou endometrióide) ou tumores malignos de células germinativas (que se originam das células que formam os óvulos). Já os cânceres que se espalham para o ovário (metastáticos) podem ser carcinomas, linfomas (câncer do sistema linfático) e melanomas (um tipo de câncer de pele).

Pesquisas ativas
906 ensaios
3342 total registrados no ClinicalTrials.gov
Publicações científicas
40 artigos
Último publicado: 2026 Feb 16
Medicamentos
11 com registro
PACLITAXEL, TOXXEL, PACLIMEIZ

Tem tratamento?

✓ 11 medicamentos específicos desta doença (registro ANVISA, FDA ou SUS/CEAF)
Ver detalhes, fases e interações →
PACLITAXELTOXXELPACLIMEIZONTAXABRAXANETAXILANPOKLIEVOTAXEL
Mais 6 moléculas em estudo para esta doença.

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
49.0
Europe
🏥
SUS: Cobertura mínimaScore: 0%
CID-10: C56
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
3 sintomas
🫃
Digestivo
2 sintomas
🧬
Pele e cabelo
1 sintomas
👂
Ouvidos
1 sintomas

+ 11 sintomas em outras categorias

Características mais comuns

—
Anormalidade do metabolismo/homeostase
—
Calcificação gonadal
—
Genitália ambígua
—
Hirsutismo
—
Distensão abdominal
—
Disgenesia gonadal com aparência feminina, masculina
18sintomas
Sem dados (18)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 18 características clínicas mais associadas, ordenadas por frequência.

Anormalidade do metabolismo/homeostaseAbnormality of metabolism/homeostasis
Calcificação gonadalGonadal calcification
Genitália ambíguaAmbiguous genitalia
HirsutismoHirsutism
Distensão abdominalAbdominal distention

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico40PubMed
Últimos 10 anos41publicações
Pico20249 papers
Linha do tempo
2026Hoje · 2026🧪 1980Primeiro ensaio clínico📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

12 genes identificados com associação a esta condição.

Curadoria gene-doença

fontes oficiais
MLH1MSH2MSH6
CTNNB1Catenin beta-1Disease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
Formation of the nephric ductSpecification of the neural plate borderSynthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)TCF dependent signaling in response to WNTTranscriptional Regulation by VENTX
MECANISMO DE DOENÇA

Colorectal cancer

A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
297.5 TPM
Cervix Ectocervix
257.8 TPM
Artéria tibial
233.5 TPM
Ovário
201.9 TPM
Cérebro - Hemisfério cerebelar
201.3 TPM
OUTRAS DOENÇAS (17)
hepatocellular carcinomasevere intellectual disability-progressive spastic diplegia syndromeovarian cancerpilomatrixoma
HGNC:2514UniProt:P35222
OPCMLOpioid-binding protein/cell adhesion moleculeDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (1)
Post-translational modification: synthesis of GPI-anchored proteins
MECANISMO DE DOENÇA

Ovarian cancer

The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
75.5 TPM
Cerebelo
60.1 TPM
Brain Frontal Cortex BA9
39.2 TPM
Córtex cerebral
24.7 TPM
Brain Anterior cingulate cortex BA24
18.9 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
ovarian cancer
HGNC:HGNC:8143UniProt:Q14982
INHBAInhibin beta A chainCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (5)
Signaling by ActivinAntagonism of Activin by FollistatinGlycoprotein hormonesSignaling by BMPTGFBR3 regulates activin signaling
EXPRESSÃO TECIDUAL(Tecido-específico)
Artéria tibial
21.2 TPM
Aorta
19.3 TPM
Artéria coronária
17.7 TPM
Fibroblastos
17.1 TPM
Pulmão
8.3 TPM
OUTRAS DOENÇAS (1)
ovarian adenocarcinoma
HGNC:6066UniProt:P08476
FOXL2Forkhead box protein L2Candidate gene tested inTolerante
VIAS BIOLÓGICAS (1)
SUMOylation of transcription factors
MECANISMO DE DOENÇA

Blepharophimosis, ptosis, and epicanthus inversus syndrome

A disorder characterized by eyelid dysplasia, small palpebral fissures, drooping eyelids and a skin fold curving in the mediolateral direction, inferior to the inner canthus. In type I BPSE (BPES1) eyelid abnormalities are associated with female infertility. Affected females show an ovarian deficit due to primary amenorrhea or to premature ovarian failure (POF). In type II BPSE (BPES2) affected individuals show only the eyelid defects.

EXPRESSÃO TECIDUAL(Tecido-específico)
Ovário
102.0 TPM
Cervix Endocervix
31.4 TPM
Cervix Ectocervix
26.6 TPM
Fallopian Tube
25.6 TPM
Pituitária
19.0 TPM
OUTRAS DOENÇAS (6)
premature ovarian failure 3blepharophimosis, ptosis, and epicanthus inversus syndromemaligant granulosa cell tumor of ovaryblepharophimosis-ptosis-epicanthus inversus syndrome type 1
HGNC:1092UniProt:P58012
PRKNE3 ubiquitin-protein ligase parkinDisease-causing germline mutation(s) inTolerante
VIAS BIOLÓGICAS (5)
AggrephagyPINK1-PRKN Mediated MitophagyAntigen processing: Ubiquitination & Proteasome degradationAmyloid fiber formationJosephin domain DUBs
MECANISMO DE DOENÇA

Parkinson disease

A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

OUTRAS DOENÇAS (4)
ovarian cancerautosomal recessive juvenile Parkinson disease 2lung canceryoung-onset Parkinson disease
HGNC:8607UniProt:O60260
PIK3CAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (10)
Signaling by LTK in cancerNephrin family interactionsIRS-mediated signallingTie2 SignalingDAP12 signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
23.2 TPM
Linfócitos
22.4 TPM
Nervo tibial
21.4 TPM
Tecido adiposo
20.5 TPM
Fibroblastos
20.5 TPM
OUTRAS DOENÇAS (28)
seborrheic keratosismegalodactylyovarian cancerhepatocellular carcinoma
HGNC:8975UniProt:P42336
AKT1RAC-alpha serine/threonine-protein kinaseDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (7)
CD28 dependent PI3K/Akt signalingVEGFR2 mediated vascular permeabilityPIP3 activates AKT signalingNegative regulation of the PI3K/AKT networkG beta:gamma signalling through PI3Kgamma
MECANISMO DE DOENÇA

Breast cancer

A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.

OUTRAS DOENÇAS (7)
ovarian cancerProteus syndromehereditary breast carcinomacolorectal cancer
HGNC:391UniProt:P31749
CDH1Cadherin-1Disease-causing germline mutation(s) inRestrito
VIAS BIOLÓGICAS (1)
Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
MECANISMO DE DOENÇA

Diffuse gastric and lobular breast cancer syndrome

A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. In addition to gastric cancer, most female mutation carriers develop lobular carcinoma of the breast.

OUTRAS DOENÇAS (9)
CDH1-related diffuse gastric and lobular breast cancer syndromeovarian cancerblepharocheilodontic syndrome 1endometrial cancer
HGNC:1748UniProt:P12830
BMP15Bone morphogenetic protein 15Candidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Ovarian dysgenesis 2

A disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads.

OUTRAS DOENÇAS (3)
ovarian dysgenesis 2immature ovarian teratoma46 XX gonadal dysgenesis
HGNC:1068UniProt:O95972
DICER1Endoribonuclease DicerCandidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (5)
MicroRNA (miRNA) biogenesisSmall interfering RNA (siRNA) biogenesistRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesisM-decay: degradation of maternal mRNAs by maternally stored factorsRegulation of MITF-M-dependent genes involved in apoptosis
MECANISMO DE DOENÇA

Pleuropulmonary blastoma

A rare pediatric intrathoracic neoplasm. The tumor arises from the lung, pleura, or both, and appears to be purely mesenchymal in phenotype. It lacks malignant epithelial elements, a feature that distinguishes it from the classic adult-type pulmonary blastoma. It arises during fetal lung development and is often part of an inherited cancer syndrome. The tumor contain both epithelial and mesenchymal cells. Early in tumorigenesis, cysts form in lung airspaces, and these cysts are lined with benign-appearing epithelium. Mesenchymal cells susceptible to malignant transformation reside within the cyst walls and form a dense layer beneath the epithelial lining. In a subset of patients, overgrowth of the mesenchymal cells produces a sarcoma, a transition that is associated with a poorer prognosis. Some patients have multilocular cystic nephroma, a benign kidney tumor.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
46.1 TPM
Tireoide
31.6 TPM
Cervix Endocervix
31.4 TPM
Útero
31.2 TPM
Ovário
30.2 TPM
OUTRAS DOENÇAS (10)
pleuropulmonary blastomaglobal developmental delay - lung cysts - overgrowth - Wilms tumor syndromegoiter, multinodular 1, with or without Sertoli-Leydig cell tumorsrhabdomyosarcoma, embryonal, 2
HGNC:17098UniProt:Q9UPY3
ERBB2Receptor tyrosine-protein kinase erbB-2Disease-causing germline mutation(s) inRestrito
VIAS BIOLÓGICAS (9)
Signaling by ERBB2Constitutive Signaling by Overexpressed ERBB2Drug-mediated inhibition of ERBB2 signalingDownregulation of ERBB2 signalingSema4D induced cell migration and growth-cone collapse
MECANISMO DE DOENÇA

Glioma

Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
130.1 TPM
Skin Sun Exposed Lower leg
118.3 TPM
Esôfago - Mucosa
113.1 TPM
Skin Not Sun Exposed Suprapubic
110.9 TPM
Tireoide
99.3 TPM
OUTRAS DOENÇAS (9)
gastric cancervisceral neuropathy, familial, 2, autosomal recessiveglioma susceptibility 1lung cancer
HGNC:3430UniProt:P04626
SMARCA4SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (10)
Formation of the beta-catenin:TCF transactivating complexNegative Regulation of CDH1 Gene TranscriptionRUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not knownRMTs methylate histone argininesFormation of neuronal progenitor and neuronal BAF (npBAF and nBAF)
MECANISMO DE DOENÇA

Rhabdoid tumor predisposition syndrome 2

A familial cancer syndrome predisposing to renal or extrarenal malignant rhabdoid tumors and to a variety of tumors of the central nervous system, including choroid plexus carcinoma, medulloblastoma, and central primitive neuroectodermal tumors. Rhabdoid tumors are the most aggressive and lethal malignancies occurring in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
81.7 TPM
Cérebro - Hemisfério cerebelar
65.7 TPM
Cerebelo
62.6 TPM
Linfócitos
61.0 TPM
Esôfago - Mucosa
57.8 TPM
OUTRAS DOENÇAS (7)
intellectual disability, autosomal dominant 16otosclerosis 12Coffin-Siris syndromeovarian small cell carcinoma
HGNC:11100UniProt:P51532

Medicamentos e terapias

GEMCITABINE HYDROCHLORIDEPhase 4

Mecanismo: DNA polymerase (alpha/delta/epsilon) inhibitor

DOXORUBICIN HYDROCHLORIDEPhase 4

Mecanismo: DNA topoisomerase II alpha inhibitor

RUCAPARIB CAMSYLATEPhase 4

Mecanismo: PARP 1, 2 and 3 inhibitor

NIRAPARIB TOSYLATE MONOHYDRATEPhase 4

Mecanismo: Poly [ADP-ribose] polymerase 2 inhibitor

OLAPARIBPhase 4

Mecanismo: PARP 1, 2 and 3 inhibitor

BEVACIZUMABPhase 4

Mecanismo: Vascular endothelial growth factor A inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

2.114 variantes patogênicas registradas no ClinVar.

🧬 SMARCA4: NM_003072.5(SMARCA4):c.1849del (p.Pro616_Val617insTer) ()
🧬 SMARCA4: NM_003072.5(SMARCA4):c.4318C>T (p.Gln1440Ter) ()
🧬 SMARCA4: NM_003072.5(SMARCA4):c.1761+2T>G ()
🧬 SMARCA4: NM_003072.5(SMARCA4):c.768del (p.Asn259fs) ()
🧬 SMARCA4: NM_003072.5(SMARCA4):c.3229dup (p.Arg1077fs) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

154 vias biológicas associadas aos genes desta condição.

Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling Cardiogenesis Germ layer formation at gastrulation Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Post-translational modification: synthesis of GPI-anchored proteins Signaling by Activin Signaling by BMP Glycoprotein hormones Antagonism of Activin by Follistatin TGFBR3 regulates activin signaling SUMOylation of transcription factors PINK1-PRKN Mediated Mitophagy Regulation of necroptotic cell death Josephin domain DUBs Aggrephagy Amyloid fiber formation Antigen processing: Ubiquitination & Proteasome degradation PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling PIP3 activates AKT signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Signaling by ALK Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions CD28 dependent PI3K/Akt signaling G alpha (q) signalling events VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Activation of BAD and translocation to mitochondria Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation MTOR signalling AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network eNOS activation AKT-mediated inactivation of FOXO1A Integrin signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 RAB GEFs exchange GTP for GDP on RABs Degradation of the extracellular matrix Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Integrin cell surface interactions Regulation of CDH1 mRNA translation by microRNAs Formation of definitive endoderm Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation MicroRNA (miRNA) biogenesis Small interfering RNA (siRNA) biogenesis tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis M-decay: degradation of maternal mRNAs by maternally stored factors Regulation of MITF-M-dependent genes involved in apoptosis Signaling by ERBB2 SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling GRB7 events in ERBB2 signaling GRB2 events in ERBB2 signaling Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Interleukin-7 signaling RMTs methylate histone arginines Chromatin modifying enzymes RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known EGR2 and SOX10-mediated initiation of Schwann cell myelination Negative Regulation of CDH1 Gene Transcription Regulation of MITF-M-dependent genes involved in pigmentation Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) Formation of the canonical BAF (cBAF) complex Formation of the polybromo-BAF (pBAF) complex Formation of the embryonic stem cell BAF (esBAF) complex Formation of the non-canonical BAF (ncBAF) complex Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado7
3Fase 316
2Fase 228
1Fase 124
·Pré-clínico31
Medicamentos catalogadosEnsaios clínicos· 6 medicamentos · 100 ensaios
✓ Aprovados — podem ser usados hoje
GEMCITABINE HYDROCHLORIDEDOXORUBICIN HYDROCHLORIDERUCAPARIB CAMSYLATENIRAPARIB TOSYLATE MONOHYDRATEOLAPARIBBEVACIZUMAB
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Câncer de ovário raro

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 57 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

100 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07851025 · Torvutatug Samrotecan Plus Bevacizumab as First-line Mainten…Recrutando
PHASE3🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +21
NCT07539844 · Study to Assess Prevalence of the Folate Receptor Alpha (FRa…Recrutando
🇧🇷 Brasil · 🇦🇷 Argentina · 🇨🇦 Canadá +2
NCT07318558 · A Clinical Trial of Sac-TMT in People With Non-HRD Positive …Recrutando
PHASE3🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +27
NCT07218809 · AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD533…Recrutando
PHASE3🇧🇷 Brasil · 🇦🇺 Austrália · 🇧🇪 Bélgica +21
NCT07213804 · A Three-Part Phase 3 Study of Sofetabart Mipitecan in Partic…Recrutando
PHASE3🇧🇷 Brasil · 🇦🇺 Austrália · 🇦🇹 Áustria +24
NCT07167433 · Observational, Bi-directional (Prospective and Retrospective…Recrutando
🇧🇷 Brasil
NCT06824467 · A Study to Evaluate the Efficacy and Safety of Sacituzumab T…Recrutando
PHASE3🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +26
NCT06819007 · Study of Trastuzumab Deruxtecan With Bevacizumab Versus Beva…Recrutando
PHASE3🇧🇷 Brasil · 🇦🇺 Austrália · 🇦🇹 Áustria +22
NCT06330064 · A Study to Evaluate the Efficacy and Safety of Ifinatamab De…Recrutando
PHASE1, PHASE2🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +15
NCT06161025 · A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With P…Recrutando
PHASE2, PHASE3🇧🇷 Brasil · 🇦🇺 Austrália · 🇨🇦 Canadá +16
NCT04590326 · A Study to Find Out How Safe REGN5668 is and How Well it Wor…Recrutando
PHASE1, PHASE2🇧🇷 Brasil · 🇧🇪 Bélgica · 🇫🇷 França +2
NCT04294927 · TUBectomy With Delayed Oophorectomy in High Risk Women to As…Recrutando
NA🇧🇷 Brasil · 🇦🇺 Austrália · 🇦🇹 Áustria +13
NCT07741968 · A Blended e-Health Intervention to Improve Fear of Progressi…Recrutando
NA🇺🇸 Estados Unidos
NCT07822646 · A Phase 3 Study of Manganese-primed Immunochemotherapy in Pa…Recrutando
PHASE3🇨🇳 China
NCT07671937 · INtegrating Systematic PatIent-Reported Evaluations in Multi…Recrutando
NA🇺🇸 Estados Unidos
NCT07860203 · Stellate Ganglion Block and Dexmedetomidine for Postoperativ…Recrutando
NA🇨🇳 China
NCT07219238 · Study to Evaluate the Diagnostic Performance of GEH300079 (6…Recrutando
PHASE2, PHASE3🇸🇪 Suécia · 🇺🇸 Estados Unidos
NCT07776691 · A Study of Raludotatug Deruxtecan With or Without Bevacizuma…Recrutando
PHASE3🇮🇱 Israel · 🇺🇸 Estados Unidos
NCT07670312 · Evaluation of XYA02 in Patients With Advanced Solid TumorsRecrutando
PHASE1, PHASE2🇦🇺 Austrália
NCT07495124 · IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Pat…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07614620 · Effect of Hypnosis in the Management of Anxiety and Chemo-in…Recrutando
NA🇫🇷 França
NCT07684612 · A Study to Investigate Mocertatug Rezetecan With Bevacizumab…Recrutando
PHASE3🇦🇺 Austrália · 🇨🇦 Canadá · 🇯🇵 Japão +1
NCT07814248 · A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07665515 · Study of CryptiVax-1001 in Maintenance Setting for Advanced …Recrutando
PHASE1🇬🇧 Reino Unido
NCT07718854 · Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Met…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07564141 · Study to Assess the Efficacy and Safety of Rina-S With or Wi…Recrutando
PHASE3🇯🇵 Japão · 🇺🇸 Estados Unidos
NCT07489287 · GB-5267 for the Treatment Platinum-Resistant Ovarian, Perito…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07341737 · SL-28 for Advanced Solid TumoursRecrutando
PHASE1, PHASE2🇦🇺 Austrália
NCT07714668 · A Clinical Study of SYS6041 Combination Therapy for Recurren…Recrutando
PHASE2🇨🇳 China
NCT07809659 · CanRisk-Based Ovarian Cancer Risk Assessment Versus Standard…Recrutando
NA🇨🇿 Tchéquia · Greece · Lithuania +1
NCT07693894 · Innovative Ovarian Cancer Biomarker AssaysRecrutando
🇨🇿 Tchéquia · Greece · Lithuania +2
NCT07749586 · A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT06412120 · Study Evaluating Safety, Tolerability, and Metabolism of Nir…Recrutando
PHASE4Nigeria · 🇺🇸 Estados Unidos
NCT07760012 · 68Ga-SorB PET/CT Imaging in Patients With Solid TumorsRecrutando
NA🇨🇳 China
NCT07708753 · A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, …Recrutando
PHASE3🇨🇳 China
NCT07638410 · Prehabilitation in High-risk Oncologic SurgeryRecrutando
NA🇺🇸 Estados Unidos
NCT07572409 · Application of Cardiophrenic Lymphadenectomy in Advanced Ova…Recrutando
NA🇨🇳 China
NCT07593092 · Phase 1, Safety and Tolerability Study of XmAb541 and XmAb80…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07702292 · [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in…Recrutando
PHASE2🇮🇹 Itália · 🇳🇱 Países Baixos
NCT07690189 · Study of NTB-928 in R/R OCRecrutando
PHASE1🇺🇸 Estados Unidos
NCT07407062 · A Study to Evaluate Folate Receptor Alpha (FRα) Expression i…Recrutando
🇮🇹 Itália
NCT07604766 · An Extension Study to Assess the Efficacy of Rina-S Compared…Recrutando
PHASE3🇨🇳 China
NCT07286266 · A Study to Investigate Mocertatug Rezetecan Compared With St…Recrutando
PHASE3🇦🇺 Austrália · 🇨🇦 Canadá · 🇯🇵 Japão +2
NCT07733505 · Normethermic Intraperitoneal Chemotherapy - a Novel Concept …Recrutando
PHASE1🇩🇰 Dinamarca
NCT07667192 · Reirradiation and Total Ablative Strategies for Recurrent Gy…Recrutando
🇵🇱 Polônia
NCT07623369 · A First-in-Human Study of HH160 in Participants With Advance…Recrutando
PHASE1🇦🇺 Austrália · 🇨🇳 China
NCT07546578 · Setting Up ctDNA Analysis on Archived Plasma SamplesRecrutando
🇮🇹 Itália
NCT07667751 · An Exploratory Study on the Use of Ipalotinib (Tislelizumab)…Recrutando
PHASE2🇨🇳 China
NCT07610798 · A Study to Evaluate the Safety, Tolerability, Pharmacokineti…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT07524322 · Study of RGT-490 in Patients With PIK3CA-Mutated Advanced So…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT04520139 · Effect of NAC on Preventing Chemo-Related Cognitive Impairme…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07764133 · Whole Body Metabolic Activity as a Reflection of Tumor Metab…Recrutando
🇺🇸 Estados Unidos
NCT06930755 · Study of NMS-03305293 in Adult Patients With Relapsed Ovaria…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07613723 · A Study to Test the Safety, Tolerability and Effect of ZI-MA…Recrutando
PHASE1🇬🇧 Reino Unido
NCT07387263 · Mainstreaming Genetics: Evaluation of a Digital Application …Recrutando
NA🇨🇦 Canadá
NCT07125209 · Cognitive Impact of Neoadjuvant Chemotherapy for Gynecologic…Recrutando
🇺🇸 Estados Unidos
NCT07557225 · 18F-T2 PET/CT Imaging for CAIX Positive Solid TumorsRecrutando
NA🇨🇳 China
NCT07371104 · Bioequivalence Study of DWZ2501 in Patients With Advanced BR…Recrutando
PHASE1South Korea
NCT07546500 · A Study of Azenosertib (ZN-c3) Versus Investigator's Choice …Recrutando
PHASE3🇦🇺 Austrália · 🇧🇪 Bélgica · 🇨🇦 Canadá +9
NCT07517198 · Dose Determining Study of EXS74539 (REC-4539) in Participant…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07736937 · Study of TUB-040 Given With Standard Ovarian Cancer Drugs in…Recrutando
PHASE1, PHASE2🇧🇪 Bélgica · Ukraine · 🇺🇸 Estados Unidos
NCT07470853 · A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07406087 · Navigation Intervention for Adolescent and Young Adult Cance…Recrutando
NA🇺🇸 Estados Unidos
NCT07144826 · Effects of a Probiotic Intervention on the Gut and Vaginal M…Recrutando
EARLY_PHASE1🇺🇸 Estados Unidos
NCT07303387 · Efficacy and Safety of the Valemetostat in Patients With Sel…Recrutando
PHASE2🇫🇷 França
NCT07424547 · Phase I Study of SYS6043 in Patients With Advanced/Metastati…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07523529 · Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid …Recrutando
PHASE1, PHASE2🇨🇳 China
NCT07589543 · Dual-Target CAR-NK Cells in Recurrent or Refractory Epitheli…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT07617753 · Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MS…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT07306559 · A Study to Test How Well Different Doses of BI 3820768 Are T…Recrutando
PHASE1🇧🇪 Bélgica · 🇫🇷 França · 🇩🇪 Alemanha +3
NCT07340164 · Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That P…Recrutando
PHASE2South Korea
NCT07503808 · A Study of IDE034 in Adult Participants With Locally Advance…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07282158 · Adapted Helping Ovarian Cancer Patients Cope Intervention to…Recrutando
NA🇺🇸 Estados Unidos
NCT07189871 · 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07432633 · [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in …Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07211659 · Trial of THEO-260 (Administered Via Intraperitoneal Route) i…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07360314 · Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsRecrutando
PHASE1🇨🇦 Canadá · 🇯🇵 Japão · 🇪🇸 Espanha +1
NCT06366490 · Safety and Immunogenicity of Innocell Autologous Cellular Im…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07304128 · A Study of PLB-002 in Advanced Solid TumorsRecrutando
PHASE1🇨🇳 China
NCT07290309 · Survivors Uniting for Remote Guided ExerciseRecrutando
NA🇺🇸 Estados Unidos
NCT07480954 · Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MS…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT06447064 · Cancer Loyalty Card Study 2 (CLOCS-2)Recrutando
🇬🇧 Reino Unido
NCT07410676 · EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembroliz…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT07410494 · Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT07491081 · EARLY Study: Evaluating the Specificity and Feasibility of t…Recrutando
NA🇦🇺 Austrália
NCT07433660 · WellSpan-THRIVE Cancer QOL StudyRecrutando
🇺🇸 Estados Unidos
NCT07402915 · Drug-drug Interaction Study With AZD5335 and Itraconazole in…Recrutando
PHASE1Georgia · 🇮🇪 Irlanda · 🇵🇹 Portugal +1
NCT07303894 · A Study of Isoquercetin in People With Ovarian CancerRecrutando
PHASE2🇺🇸 Estados Unidos
NCT07280312 · Ultrasound Microvessel Imaging for the Evaluation of Ovarian…Recrutando
NA🇺🇸 Estados Unidos
NCT07361471 · Identification of Genetic, Phenotypic, Clinical, Biological …Recrutando
NA🇫🇷 França
NCT06815497 · Telmisartan in Combination With Cytotoxic Regimens in Platin…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07480785 · TEAS Combined With Triple Antiemetic Drugs to Prevent PONV i…Recrutando
NA🇨🇳 China
NCT07226427 · A First-in-Human Study of MEN2501 in Participants With Plati…Recrutando
PHASE1🇦🇺 Austrália · 🇪🇸 Espanha · 🇺🇸 Estados Unidos
NCT07676370 · PROV-MESH: Prophylactic Ovarian Cancer MESHRecrutando
NA🇪🇸 Espanha
NCT07311577 · Disitamab Vedotin Combined With Platinum and Bevacizumab as …Recrutando
PHASE2🇨🇳 China
NCT07447050 · Riluzole For Preventing Cognitive Dysfunction in Ca Pts Rece…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07586826 · Romiplostim N01 Plus ATRA for Persistent Isolated Chemothera…Recrutando
PHASE2🇨🇳 China
NCT06717295 · The CCANED-CIPHER Study: Early Cancer Detection and Treatmen…Recrutando
🇦🇷 Argentina · Nigeria · 🇬🇧 Reino Unido
NCT07444814 · Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT07498829 · Population Based Germline Testing for Early Detection and Pr…Recrutando
NA🇬🇧 Reino Unido

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
39 papers (10 anos)
#1

Endometrial pathology and surgical extent in ovarian adult granulosa cell tumor: associations with stage and survival.

American journal of obstetrics and gynecology2026 Feb 16

Este estudo revelou que a presença de sangramento uterino anormal ou patologias endometriais (hiperplasia ou câncer) está associada a um estágio mais baixo do tumor de células da granulosa (TCG) ovariano, sugerindo uma detecção mais precoce que não afeta negativamente a sobrevida geral das pacientes. Para médicos e pacientes, o estadiamento cirúrgico completo não demonstrou melhorar a sobrevida livre de progressão, embora estágios mais avançados (IC ou superior) continuem associados a um maior risco de recorrência.

🇧🇷 traduzido
#2

Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type.

iScience2025 Feb 21

O carcinoma de pequenas células do ovário, tipo hipercalcêmico (SCCOHT), é um câncer raro e agressivo que afeta mulheres jovens. Este estudo aprofunda a compreensão de sua biologia, mostrando que a perda de proteínas SMARCA4/SMARCA2 altera "super-enhancers" que regulam genes de desenvolvimento, como os do sistema nervoso. Crucialmente, a pesquisa demonstrou que o composto triptolida (e seu pró-fármaco minnelide) é altamente eficaz contra células de SCCOHT e inibe o crescimento tumoral em modelos pré-clínicos, oferecendo uma promissora nova abordagem terapêutica ao atuar sobre esses "super-enhancers".

🇧🇷 traduzido
#3

Experiences of radiotherapy for treatment of Granulosa Cell Tumor of the ovary: insights from the GCT-survivor sisters.

Gynecologic oncology2025 Dec

O tratamento ideal para o Tumor de Células da Granulosa (TCG) ainda é incerto, e a radioterapia, embora não seja comum, é utilizada para a doença recorrente, com sua aplicação variando significativamente entre diferentes países. A maioria das pacientes que receberam radioterapia relata experiências positivas, como eficácia no tratamento e melhoria na qualidade de vida, apesar de algumas terem sofrido efeitos colaterais severos. Isso ressalta a importância de mais pesquisas para estabelecer diretrizes claras sobre o momento e a forma mais eficaz de usar a radioterapia no manejo do TCG.

🇧🇷 traduzido
#4

Multiplexed Imaging Mass Cytometry Reveals Tumor-immune Microenvironment-dependent Hormone Receptor Expression in Adult-Type Ovarian Granulosa Cell Tumors.

Cancer research communications2025 Oct 01

Este estudo inovador sobre os raros tumores de células da granulosa do ovário (AGCT), com poucas opções de tratamento para casos recorrentes, revelou a existência de dois subtipos distintos: AGCT-1 e AGCT-2. Esses subtipos diferem significativamente em sua composição celular, atividade imune (com mais macrófagos em tumores recorrentes) e sinais hormonais, como a expressão do receptor de progesterona. Essa nova classificação é crucial para guiar abordagens terapêuticas mais personalizadas e eficazes, oferecendo novas esperanças para pacientes com esta malignidade rara.

🇧🇷 traduzido
#5

The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study.

Gynecologic oncology2025 Nov

Este estudo sobre o câncer de ovário de células claras avançado (OCCC) revela um prognóstico desfavorável, com a quimioterapia neoadjuvante (NACT) não apresentando melhorias significativas na ressecabilidade ou sobrevida em comparação com a cirurgia citorredutora primária (PCS). No entanto, o esforço cirúrgico máximo para atingir doença residual mínima (RD ≤10mm ou idealmente RD0) foi crucial, associando-se a melhores resultados de sobrevida e sublinhando a importância da qualidade da citorredução para esses pacientes.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMC8 artigos no totalmostrando 41

2026

Endometrial pathology and surgical extent in ovarian adult granulosa cell tumor: associations with stage and survival.

American journal of obstetrics and gynecology
2025

Experiences of radiotherapy for treatment of Granulosa Cell Tumor of the ovary: insights from the GCT-survivor sisters.

Gynecologic oncology
2025

Multiplexed Imaging Mass Cytometry Reveals Tumor-immune Microenvironment-dependent Hormone Receptor Expression in Adult-Type Ovarian Granulosa Cell Tumors.

Cancer research communications
2025

The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study.

Gynecologic oncology
2025

Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.

Cancer research
2025

Targeting Mediator Kinase Cyclin-Dependent Kinases 8/19 Potentiates Chemotherapeutic Responses, Reverses Tumor Growth, and Prolongs Survival from Ovarian Clear Cell Carcinoma.

Cancers
2025

Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
2025

Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type.

iScience
2025

CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds.

Molecular oncology
2024

GW0742 as a Potential TRα and TRβ Antagonist Reduces the Viability and Metabolic Activity of an Adult Granulosa Tumour Cell Line and Simultaneously Upregulates TRβ Expression.

Cancers
2024

Epigenetic Therapy in a Rare Ovarian Cancer - A Double-Edged Sword.

The New England journal of medicine
2024

Single-molecule epiallelic profiling of DNA derived from routinely collected Pap specimens for noninvasive detection of ovarian cancer.

Clinical and translational medicine
2024

Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

Pleura and peritoneum
2024

A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
2024

Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand.

The Australian &amp; New Zealand journal of obstetrics &amp; gynaecology
2024

Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report.

Gynecologic oncology reports
2024

Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.

Histopathology
2024

Top advances of the year: Ovarian cancer.

Cancer
2023

Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.

Gynecologic oncology
2023

Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.

Gynecologic oncology
2023

How social media can help to understand treatment experiences of survivors of rare cancers: Findings from the Granulosa Cell Tumor Survivor Sisters Facebook group member survey.

Cancer
2023

A Rare Case of Ruptured Malignant Ovarian Brenner Tumor.

The American journal of case reports
2022

Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Anticancer research
2022

Rare Ovarian Cancer's First Positive Trial.

Cancer discovery
2022

Non-Gestational Ovarian Choriocarcinoma: A Rare Ovarian Cancer Subtype.

Diagnostics (Basel, Switzerland)
2022

Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus.

Gynecologic oncology reports
2022

DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.

Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
2021

Low-Grade Ovarian Serous Adenocarcinoma with Lymph Node Metastasis in Neck.

Diagnostics (Basel, Switzerland)
2021

Immunotherapy in rare ovarian cancer.

Current opinion in oncology
2021

Familial Occurrence of Adult Granulosa Cell Tumors: Analysis of Whole-Genome Germline Variants.

Cancers
2021

Malignant struma ovarii: surgical, histopathological and survival outcomes for thyroid-type carcinoma of struma ovarii with recommendations for standardising multi-modal management. A retrospective case series sharing the experience of a single institution over 10 years.

Archives of gynecology and obstetrics
2020

Confronting a rare ovarian cancer during lockdown.

The Lancet. Respiratory medicine
2020

MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2020

Natural killer cell impairment in ovarian clear cell carcinoma.

Journal of leukocyte biology
2020

Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.

Clinical cancer research : an official journal of the American Association for Cancer Research
2020

Low-grade serous ovarian cancer: State of the science.

Gynecologic oncology
2019

Management of Rare Ovarian Cancer Histologies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2019

Metastasis of ovarian cancer to the bile duct: a case report.

Surgical case reports
2019

Ovarian Clear Cell Carcinoma in Cowden Syndrome.

Journal of the National Comprehensive Cancer Network : JNCCN
2018

Identification of Driver Mutations in Rare Cancers: The Role of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT).

Methods in molecular biology (Clifton, N.J.)
2017

Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma.

Frontiers in oncology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Câncer de ovário raro.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Câncer de ovário raro e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

É uma neoplasia maligna pouco frequente que acomete o ovário de forma primária ou por metástases. Pode se originar a partir de carcinomas, células germinativas ou tecidos estromais do ovário.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

7 publicações do grafo RarasNet (PubMed) · 8 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. ORPHA:213500
    Orphanet
  2. GARD:7295
    GARD (NIH)
  3. Q172341
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Câncer de ovário raro. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/cancer-de-ovario-raro

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Câncer de ovário raro
Compêndio · Raras BR

Câncer de ovário raro

ORPHA:213500 · MONDO:0008170
Prevalência
1-5 / 10 000
CID-10
C56 · Neoplasia maligna do ovário
CID-11
Ensaios
906 ativos
Medicamentos
6 registrados
Prevalência
49.0 (Europe)
MedGen
UMLS
C3810371
Repurposing
10 candidatos
altretamine — DNA synthesis inhibitor
carboplatin — DNA alkylating agent|DNA inhibitor
cisplatin — DNA alkylating agent|DNA synthesis inhibitor
+7 outros
EuropePMC
Wikidata
Wikipedia
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Genética mendeliana
fonte: OMIM
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Moléculas estudadas na doença
fonte: OpenTargets
Rara